Stem Cells

<p>SLLK is a control peptide for LSKL.</p>

<p>WAY-296817 inhibits CK1, potential for circadian rhythm and inflammation research.</p>

<p>Wnt pathway inhibitor 3 is a potent AC1 inhibitor with an IC50 value of 45 nM.Wnt pathway inhibitor 3 has antiproliferative activity and can be used in studies</p>

<p>Foxy-5 acetate: Wnt 5A agonist, inhibits cancer cell migration/invasion, boosts calcium signaling, doesn't activate β-catenin.</p>

<p>RBPJ Inhibitor-1 (RIN1), a compound that impedes the functional interaction between RBPJ and SHARP, effectively inhibits NOTCH-dependent tumor cell</p>

<p>VT104 is a potent and orally active YAP/TAZ inhibitor for cancer research.Cost-effective and quality-assured.</p>

<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>

<p>GSK-3β inhibitor22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM, showing potential for Alzheimer's disease research.</p>

<p>A unique collection of 237 Wnt/Hedgehog/Notch signaling targeted compounds for high throughput and high content screening;</p>

<p>Jagged-1 （188-204）is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin.</p>

<p>GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay.</p>

<p>STAT3-IN-39 (compound 10K) is an orally active inhibitor of STAT3, demonstrating effective inhibition of STAT3 phosphorylation with an IC50 of 0.47 μM in NIH-3T3 cells. It hinders TGF-β1-induced fibrotic responses and prevents epithelial-mesenchymal transition in A549 cells. STAT3-IN-39 is applicable for research related to idiopathic pulmonary fibrosis.</p>

<p>pan-TEAD-IN-1 (Compound 3) is an orally active pan-inhibitor of TEAD, disrupting its interaction with coactivators YAP/TAZ by targeting the palmitoylation site of TEAD. This inhibition leads to the downregulation of oncogene transcription, such as Ctgf and Cyr61, within the Hippo signaling pathway. Demonstrating outstanding efficacy, pan-TEAD-IN-1 has an IC50 of 0.36 nM for luciferase and 1.52 nM for H226 cells, along with favorable pharmacokinetic properties (AUC0–∞= 228.7 μg/mL·min, T1/2= 183.9 min). The compound significantly inhibits tumor growth in xenograft models of TEAD-dependent cancers, indicating its potential for research in these cancer types.</p>

<p>STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.</p>

<p>Wnt/β-catenin agonist 3 is a Wnt/beta-catenin agonist.</p>

<p>Super-TDU (1-31) TFA, a peptide, inhibits YAP-TEAD; it has strong anti-tumor effects in gastric cancer models.</p>

<p>Plant 14-3-3-IN-1 (Compound 2) is an inhibitor of the Arabidopsis thaliana 14-3-3 protein, with an IC50 of 1.21 μM. It exhibits varying inhibitory activity against different 14-3-3 isoforms and promotes the closure of leaf stomata.</p>

<p>TEAD-IN-16 (compound BC-011) is a potent inhibitor of TEAD, with an IC50 of 72.43 μM. This compound plays a significant role in cancer research.</p>

<p>1(R),2(S)-epoxy Cannabidiol (Compound 2a) is a structural analog of phytocannabinoids, exhibiting significant inhibitory activity on the Wnt/β-catenin pathway. It holds potential for research as a neuroprotective agent.</p>

<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>

<p>GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.</p>

<p>YAP-IN-1 (Compound (+)-1) is an autophagy inhibitor specifically targeting YAP1. It binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM, promoting its degradation through the chaperone-mediated autophagy (CMA) pathway. This process inhibits the Rab7-mediated fusion of autophagosomes with lysosomes and decreases autophagy levels without affecting lysosomal function. YAP-IN-1 shows potential for cancer research, including in hepatocellular carcinoma and breast cancer.</p>

<p>NIBR-LTSi is a selective LATS kinase inhibitor that also activates YAP signaling, promotes tissue stem cell expansion and tissue regeneration in vitro/vivo.</p>

<p>Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.</p>

<p>ROCK2-IN-9 (compound 7u), a selective ROCK2 inhibitor with an IC50 value of 36.8 nM, demonstrates anticancer properties by impeding cancer cell migration and invasion. This action is achieved through the regulation of various actin cytoskeleton cellular activities. It holds potential for use in breast cancer research.</p>

<p>Akt/ROCK-IN-1 (B12) is a dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively.</p>

<p>MR24 is a derivative of G-5555 and acts as an inhibitor of mammalian STE20-like (MST) kinases. It selectively targets MST3 and MST4, with EC50 values of 57 nM and 583 nM, respectively.</p>

<p>BAY 593 functions as an inhibitor of geranylgeranyltransferase-I (GGTase-I), effectively preventing the activation of Rho-GTPases and consequently inactivating YAP1/TAZ signaling pathways. It has been shown to inhibit tumor growth dose-dependently in xenograft mouse models, exhibiting IC50 values of 38.4 nM in MT-1080 cells and 564 nM in MDA-MB-231 cells, as well as in PXF 541 xenografts.</p>

<p>CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.</p>

<p>IWP-3 is a potent inhibitor of Wnt production with an IC50 of 40 nM. It inhibits Porcupine (Porcn), blocking the palmitoylation of Wnt proteins, and moderately inhibits CK1γ3 and CK1ε, but does not inhibit CK1α [1] [2].</p>

<p>PF-5006739: potent, selective CK1δ/ε inhibitor (IC50: 3.9/17.0 nM); may treat psychiatric disorders, improves glucose tolerance, reduces opioid seeking.</p>

<p>Gamma-secretase modulator 3 (γ-secretase modulator 3) is a γ-secretase modulator that reduces Aβ production.</p>

<p>Stafib-1 is a selective inhibitor of STAT5β targeting SH2 domain with an IC50 of 154 nM and a Ki of 44 nM.</p>

<p>YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor (IC50 &lt;0.100 μΜ) for the study of abnormal immune function and cancer.</p>

<p>Anti-GPC3 Antibody (4L576) is an antibody targeting GPC3. Anti-GPC3 Antibody (4L576) can be used in ELISA, WB, IF.</p>

<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>

<p>Anti-SOST Antibody (3R170) is an antibody targeting SOST. Anti-SOST Antibody (3R170) can be used in ELISA, IHC.</p>

<p>Anti-NANOG Antibody (1M448) is a Mouse antibody targeting NANOG. Anti-NANOG Antibody (1M448) can be used in ELISA, WB, ICC, IF, FCM.</p>

<p>Anti-5T4/TPBG Antibody (9P872) is an antibody targeting 5T4/TPBG. Anti-5T4/TPBG Antibody (9P872) can be used in ELISA, FCM.</p>

<p>Ceftriaxone Sodium is a sporotaxin antibiotic that inhibits GSK3β and Aurora B. It is used in the study of sepsis and infective endocarditis.</p>

<p>Bintrafusp alfa (M7824) is a protein consisting of the extracellular structural domain of TGF-βRII with a monoclonal antibody to human immunoglobulin G1.</p>

<p>Verosudil (AR-12286), a ROCK1/2 inhibitor (Ki: 2 nM), lowers intraocular pressure in mice by enhancing aqueous outflow.</p>

<p>SGC-CK2-1, a CK2 inhibitor, is a inducer of insulin production and secretion in pancreatic β-cells.</p>

<p>IBS008738 is a TAZ activator that stabilises TAZ and increases unphosphorylated TAZ levels in C2C12 cells, upregulates MyoD-dependent gene transcription.</p>

<p>GSK269962A hydrochloride (GSK 269962 hydrochloride) is a ROCK inhibitor with anti-inflammatory and vasodilatory effects and inhibits ROCK1 and ROCK2.</p>

<p>Cotosudil is a ROCK kinase inhibitor with antihypertensive activity used to treat or prevent neurodegenerative diseases.</p>

<p>Belumosudil mesylate (KD025 mesylate) is a ROCK2 inhibitor with antifibrotic activity, and can be used in chronic graft-versus-host disease research.</p>

<p>CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling.</p>

<p>Teplinovivint is a potent inhibitor of the Wnt/β-catenin signaling pathway, demonstrating anti-inflammatory properties with potential utility in tendinopathy</p>

<p>exo-IWR-1 (exo-IWR 1) is an inactive stereoisomer of Endo-IWR-1,and is a negative control of IWR-1. IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin</p>